Genor Biopharma, Walvax’s, Partners With Mabspace Biosciences To Discover And Develop Novel Antibody Therapeutics
SUZHOU, China--(BUSINESS WIRE)--MabSpace Biosciences Co., Ltd announced today that it has signed a collaborative contract of a novel therapeutic antibody with Genor Biopharma Co. Ltd (GenorBio), the mAb division of Walvax Group, one of the leading therapeutic antibody development companies in China.
“We are attracted by MabSpace’s capability in discovering novel differentiated antibody therapeutic candidates with its immune tolerance breaking technology and the access to fully human antibody transgenic mice platform”
According to the agreement, MabSpace will be responsible for the discovery and selection of fully human lead antibodies and GenorBio for the further development of the selected candidate molecules. GenorBio will own exclusive global rights on the resulting therapeutic candidates for the nominated targets, while MabSpace will receive upfront R&D funding, regulatory milestones and royalty on global sales.
“We are attracted by MabSpace’s capability in discovering novel differentiated antibody therapeutic candidates with its immune tolerance breaking technology and the access to fully human antibody transgenic mice platform,” commented Dr. Joe Zhou, CEO of Genor Biopharma and VP of Research of Walvax Group.
“MabSpace is honored to work with GenorBio who has extensive capabilities and experience in antibody process and product development,” said Dr. Xueming Qian, Chairman and CEO of MabSpace.
About MabSpace Biosciences
MabSpace Biosciences Co., Ltd. is a biotechnology company focused on the discovery and early development of antibody based therapeutics. The key advantage of its proprietary immune tolerance breaking technology (IMTB) is the ability to obtain antibodies targeting diverse epitope space on a given target, including those epitopes with high degree of cross-species identity in amino acid. MabSpace has an in-licensed fully human antibody transgenic mice platform. MabSpace is headquartered in Hong Kong and has an R&D subsidiary with fully-integrated in vitro and in vivo pharmacology profiling capabilities in Biobay, Suzhou Industrial Park. Visit www.mabspacebio.com for more information.
About Walvax and GenorBio
Walvax is the first vaccine company listed on ChiNext. Since its historical IPO in 2010, Walvax has expanded and built itself into a leading and fully integrated biopharmaceutical group, with its business covering vaccines, mAbs and blood-derived products. Walvax acquired Genor at the end of 2013 as a major strategic move.
Founded in 2007, Genor Biopharma Co. Ltd. is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibodies (mAbs) and Fc-fusion proteins. Visit www.genorbio.com for more information.